Haemonetics Corp (HAE) — SEC Filings
Haemonetics Corp (HAE) — 35 SEC filings. Latest: 8-K (May 7, 2026). Includes 17 8-K, 7 SC 13G/A, 5 10-Q.
View Haemonetics Corp on SEC EDGAR
Overview
Haemonetics Corp (HAE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Haemonetics Corporation reported a net income of $38.684 million for the three months ended September 27, 2025, an increase of 14.3% from $33.831 million in the prior year period. However, net revenues decreased by 5.3% to $327.315 million from $345.511 million in the same period. For the six months
Sentiment Summary
Across 35 filings, the sentiment breakdown is: 4 bullish, 1 bearish, 29 neutral, 1 mixed. The dominant filing sentiment for Haemonetics Corp is neutral.
Filing Type Overview
Haemonetics Corp (HAE) has filed 17 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 1 SC 13G, 7 SC 13G/A, 1 8-K/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (35)
Risk Profile
Risk Assessment: Of HAE's 28 recent filings, 0 were flagged as high-risk, 12 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $327,315,000 |
| Net Income | $38,684,000 |
| EPS | $0.81 |
| Cash Position | $296,426,000 |
| Operating Margin | 17.86% |
Key Executives
- Persons of the Company
- Brenda L. Foster
- Brian J. Smith
- Brenda L. Laursen
- Dr. David M. R. Johnson
- Ms. Sarah E. O'Hara
Industry Context
Haemonetics operates in the medical device industry, specifically focusing on blood and plasma management and related technologies. The sector is characterized by innovation, stringent regulatory requirements, and consolidation. Companies like Haemonetics compete on product efficacy, safety, and cost-effectiveness, often requiring significant R&D investment and strategic acquisitions to maintain market position.
Top Tags
healthcare (4) · Medical Devices (3) · shareholder-vote (3) · financials (3) · 10-Q (3) · 8-K (3) · regulatory-filing (3) · acquisition (3) · plasma (3) · amendment (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Revenues | $327.3M | Decreased by 5.3% for the three months ended September 27, 2025, compared to $345.5M in the prior year. |
| Net Income | $38.7M | Increased by 14.3% for the three months ended September 27, 2025, from $33.8M in the prior year. |
| Gross Profit | $194.7M | Increased for the three months ended September 27, 2025, from $187.4M in the prior year, despite revenue decline. |
| Cost of Goods Sold | $132.6M | Decreased by 16.1% for the three months ended September 27, 2025, from $158.1M in the prior year. |
| Operating Income | $58.5M | Increased by 13.1% for the three months ended September 27, 2025, from $51.7M in the prior year. |
| Impairment of Intangible Assets | $8.6M | Increased significantly for the three months ended September 27, 2025, from $2.4M in the prior year. |
| Attune Medical Acquisition Price | $176.2M | Net purchase price for the acquisition completed on April 1, 2024. |
| Common Stock Outstanding | 46,809,672 | Shares outstanding as of October 31, 2025. |
| Total Revenue | $325.5M | Increased by 10.2% from $295.4 million in Q1 FY25 |
| Revenue Growth | 10.2% | Year-over-year increase in total revenue |
| Net Income Growth | 25.4% | Year-over-year increase in net income |
| Diluted EPS | $1.15 | Increased from $0.91 in Q1 FY25 |
| Plasma Segment Revenue | $128.7M | Grew by 15.1% in Q1 FY26 |
| Operating Expenses | $105.3M | Increased from $98.1 million in Q1 FY25 |
| SEC File Number | 001-14041 | Identifies the company's filing history with the SEC. |
Forward-Looking Statements
- {"claim":"Haemonetics Corp. stock may experience short-term selling pressure due to the reduction in institutional ownership.","entity":"Haemonetics Corp.","targetDate":"Q1 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Haemonetics Corp (HAE)?
Haemonetics Corp has 35 recent SEC filings from Jan 2024 to May 2026, including 17 8-K, 7 SC 13G/A, 5 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of HAE filings?
Across 35 filings, the sentiment breakdown is: 4 bullish, 1 bearish, 29 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Haemonetics Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Haemonetics Corp (HAE) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Haemonetics Corp?
Key financial highlights from Haemonetics Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for HAE?
The investment thesis for HAE includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Haemonetics Corp?
Key executives identified across Haemonetics Corp's filings include Persons of the Company, Brenda L. Foster, Brian J. Smith, Brenda L. Laursen, Dr. David M. R. Johnson and 1 others.
What are the main risk factors for Haemonetics Corp stock?
Of HAE's 28 assessed filings, 0 were flagged high-risk, 12 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Haemonetics Corp?
Recent forward-looking statements from Haemonetics Corp include guidance on {"claim":"Haemonetics Corp. stock may experience short-term selling pressure due to the reduction in institutional owner.